Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma

BACKGROUND The objective of this multicentre, randomised, double blind, parallel group study was to compare the efficacy and safety of the addition of salmeterol with that of doubling the dose of fluticasone propionate in asthmatic patients not controlled by a low or intermediate dose of inhaled corticosteroids. METHODS After a four week run in period of treatment with fluticasone propionate (100 μg twice daily if pre-trial dose was 400–600 μg inhaled corticosteroids or 250 μg twice daily if pre-trial dose was 800–1200 μg inhaled corticosteroids), 274 patients were randomised to treatment for 12 weeks with either salmeterol 50 μg twice daily plus the run in dose of fluticasone propionate or twice the run in dose of fluticasone propionate (200 or 500 μg twice daily). Outcome measures were daily records of peak expiratory flow (PEF), symptom scores, and clinic lung function. RESULTS The improvements in both the morning and evening PEF were better in the salmeterol than in the fluticasone propionate group, the mean increase in morning PEF being 19 l/min higher (95% CI 11.0 to 26.1) and in evening PEF being 16 l/min (95% CI 18.4 to 24.0) higher in the salmeterol group. The increase in forced expiratory volume in one second (FEV1) was 0.09 l greater in the salmeterol group than in the fluticasone propionate group after four weeks of treatment (95% CI 0.01 to 0.18), but not after 12 weeks. Both regimens showed an increase in symptom free days and a reduction in the need for rescue salbutamol both during the day and the night, but these improvements were greater in the salmeterol group. There were no significant differences between the groups in adverse effects or in the number of rescue courses of oral corticosteroids. CONCLUSIONS In this group of patients still symptomatic despite 100 or 250 μg fluticasone propionate twice daily, the addition of salmeterol caused a greater improvement in lung function and symptom control than doubling the dose of fluticasone propionate.

[1]  J. FitzGerald,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. , 1998, The New England journal of medicine.

[2]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[3]  R. Roorda,et al.  One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. , 1997, American journal of respiratory and critical care medicine.

[4]  D. Yates,et al.  An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. , 1996, American journal of respiratory and critical care medicine.

[5]  J. Walters,et al.  Salmeterol tachyphylaxis in steroid treated asthmatic subjects. , 1996, Thorax.

[6]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[7]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[8]  D. Cockcroft,et al.  Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. , 1996, Chest.

[9]  D. Cockcroft,et al.  Rapid onset of tolerance to the bronchoprotective effect of salmeterol. , 1995, Chest.

[10]  D. Yates,et al.  Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. , 1995, American journal of respiratory and critical care medicine.

[11]  B. Lipworth,et al.  Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. , 1995, Thorax.

[12]  A. Kamada.  EFFECT OF 22 MONTHS OF TREATMENT WITH INHALED CORTICOSTEROIDS AND/OR BETA-2- AGONISTS ON LUNG FUNCTION, AIRWAY RESPONSIVENESS, AND SYMPTOMS IN CHILDREN WITH ASTHMA , 1994, Pediatrics.

[13]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[14]  B. Lipworth,et al.  Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. , 1994, Respiratory medicine.

[15]  A. Zwinderman,et al.  Long-Term Effects of a Long-acting ??2-Adrenoceptor Agonist, Salmeterol, on Airways Hyperresponsiveness in Patients with Mild Asthma , 1993 .

[16]  J. Kemp,et al.  A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.

[17]  A. Zwinderman,et al.  Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. , 1992, The New England journal of medicine.

[18]  J. Palmer,et al.  A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. , 1992, The European respiratory journal.

[19]  M. Hughes,et al.  Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. , 1992, The American review of respiratory disease.

[20]  T. Haahtela,et al.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. , 1991, The New England journal of medicine.

[21]  C. Madden.  Regular inhaled beta-agonist treatment in bronchial asthma , 1991 .

[22]  E. Juniper,et al.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. , 1990, The American review of respiratory disease.

[23]  J. Hedner,et al.  Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. , 1990, The American review of respiratory disease.